🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Kim N.

BC Cancer Agency

ORCID: 0000-0002-3782-7226

Also affiliated with University of British Columbia, Asian Institute of Technology, BC Cancer Foundation

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial”.

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

The Lancet(2024)10.1016/s0140-6736(24)01653-2
N/A
4.3DataRank · unranked
287 citations

Daniel Castellano, Ken Herrmann, Johann S. De Bono, Neal D. Shore, Kim N. +18 more

Autoantibody landscape of advanced prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.02.074575
N/A
0DataRank · unranked
0 citations

Winston Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha +25 more

5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.148
N/A
0DataRank · unranked
3 citations

Shuang G. Zhao, Eric J. Small, Yuhong Ning, Corinne Maurice‐Dror, Adam Foye +15 more

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Cancer Research(2022)10.1158/0008-5472.can-22-1123
N/A
0DataRank · unranked
67 citations

Shuang G. Zhao, Samuel Levy, Meng Zhang, Yuhong Ning, Raunak Shrestha +58 more

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.02.010
N/A
0DataRank · unranked
58 citations

Michael T. Schweizer, Kim N., Rahul Aggarwal, Neeraj Agarwal, James L. Gulley +9 more

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02661
N/A
0DataRank · unranked
29 citations

Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher J. Logothetis +15 more

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102862
N/A
0DataRank · unranked
26 citations

Andrei Gafita, Johann S. De Bono, Oliver Sartor, Kim N., Bernd J. Krause +11 more

Autoantibody Landscape in Patients with Advanced Prostate Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1966
N/A
0DataRank · unranked
20 citations

Winston Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha +26 more

Plasma Cell–Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer

Cancer Research(2024)10.1158/0008-5472.can-24-2052
N/A
0DataRank · unranked
13 citations

Aslı D. Munzur, Edmond M. Kwan, Clara C. Y. Seo, Benjamin J. Hauk, Karan Parekh +16 more